Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405
| Autor: | Kimmie Ng, Charles D. Blanke, Robert J. Mayer, Eileen M. O'Reilly, Brendan J. Guercio, Kaori Sato, Jeffrey A. Meyerhardt, Bert H. O'Neil, Alan P. Venook, Fang-Shu Ou, Howard S. Hochster, Sui Zhang, James N. Atkins, Blase N. Polite, Richard M. Goldberg, Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, James Edward Shaw, Federico Innocenti, Heinz-Josef Lenz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Colorectal cancer Clinical Sciences Oncology and Carcinogenesis Physical activity Group B Cohort Studies 03 medical and health sciences 0302 clinical medicine Clinical Research Surveys and Questionnaires Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Clinical Trials Prospective Studies Oncology & Carcinogenesis 030212 general & internal medicine Prospective cohort study Exercise Aged Randomized Controlled Trials as Topic Cancer business.industry ORIGINAL REPORTS Middle Aged medicine.disease United States Colo-Rectal Cancer Phase III as Topic Clinical trial Leukemia Good Health and Well Being Clinical Trials Phase III as Topic 030220 oncology & carcinogenesis Disease Progression Female Colorectal Neoplasms Digestive Diseases business Cohort study |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 29 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | PURPOSE Regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored. PATIENTS AND METHODS We conducted a prospective cohort study nested in Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: NCT00265850 ), a National Cancer Institute–sponsored phase III trial of systemic therapy for mCRC. Within 1 month after therapy initiation, patients were invited to complete a validated questionnaire that reported average physical activity over the previous 2 months. On the basis of responses, we calculated metabolic equivalent task (MET) hours per week to quantify physical activity. The primary end point of the clinical trial and this companion study was overall survival (OS). Secondary end points included progression-free survival (PFS) and first grade 3 or greater treatment-related adverse events. To minimize confounding by poor and declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and used Cox proportional hazards regression analysis to adjust for known prognostic factors, comorbidities, and weight loss. RESULTS The final cohort included 1,218 patients. Compared with patients engaged in less than 3 MET hours per week of physical activity, patients engaged in 18 or more MET hours per week experienced an adjusted hazard ratio for OS of 0.85 (95% CI, 0.71 to 1.02; PTrend = .06) and for PFS of 0.83 (95% CI, 0.70 to 0.99; PTrend = .01). Compared with patients engaging in less than 9 MET hours per week, patients engaging in 9 or more MET hours per week experienced an adjusted hazard ratio for grade 3 or greater treatment-related adverse events of 0.73 (95% CI, 0.62 to 0.86; PTrend < .001). CONCLUSION Among patients with mCRC in Cancer and Leukemia Group B (Alliance)/SWOG 80405, association of physical activity with OS was not statistically significant. Greater physical activity was associated with longer PFS and lower adjusted risk for first grade 3 or greater treatment-related adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|